Literature DB >> 24326827

Utility of LRF/Pokemon and NOTCH1 protein expression in the distinction between nodular lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma.

Olga Bohn1, Takahiro Maeda, Alexander Filatov, Andrea Lunardi, Pier Paolo Pandolfi, Julie Teruya-Feldstein.   

Abstract

Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) are considered separate entities with different prognosis and treatment. However, morphologic features can be similar and immunohistochemical studies are essential in the distinction; thus, determination of additional biomarkers is of utmost importance. LRF/Pokemon is a proto-oncogene, an interacting partner co-expressed with BCL6 in germinal centers and highly expressed in diffuse large B-cell lymphoma and follicular lymphoma. Conversely, loss of the LRF gene in mouse hematopoietic stem cells results in complete block of early B cell development with concomitant Notch de-repression, indicating its critical role in B versus T cell fate decision at the hematopoietic stem cell stage. For the first time, we show that LRF/Pokemon is predominantly expressed in NLPHL cases as is BCL6 with low to absent NOTCH1 protein expression; while Hodgkin Reed-Sternberg (HRS) cells in CHL show low to absent BCL6 and LRF/Pokemon expression with higher NOTCH1 expression. We illustrate a potential functional interaction between LRF and BCL6 in NLPHL pathogenesis, and differential expression of LRF/Pokemon and NOTCH1 proteins in CHL thus showing differential expression, making for an additional diagnostic marker and therapeutic target.

Entities:  

Keywords:  Hodgkin lymphoma; LRF; Pokemon; classical Hodgkin lymphoma (cHL); nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)

Mesh:

Substances:

Year:  2013        PMID: 24326827      PMCID: PMC3971474          DOI: 10.1177/1066896913513833

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  34 in total

1.  The role of chemokines in Hodgkin's disease.

Authors:  J Teruya-Feldstein; G Tosato; E S Jaffe
Journal:  Leuk Lymphoma       Date:  2000-07

Review 2.  Notch signaling in hematopoiesis and early lymphocyte development.

Authors:  David Allman; Jon C Aster; Warren S Pear
Journal:  Immunol Rev       Date:  2002-09       Impact factor: 12.988

3.  Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene.

Authors:  J M Davies; N Hawe; J Kabarowski; Q H Huang; J Zhu; N J Brand; D Leprince; P Dhordain; M Cook; G Morriss-Kay; A Zelent
Journal:  Oncogene       Date:  1999-01-14       Impact factor: 9.867

Review 4.  Hodgkin's disease: a tumor with disturbed immunological pathways.

Authors:  H J Gruss; A Pinto; J Duyster; S Poppema; F Herrmann
Journal:  Immunol Today       Date:  1997-04

5.  Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia.

Authors:  J Teruya-Feldstein; E S Jaffe; P R Burd; D W Kingma; J E Setsuda; G Tosato
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

6.  A requirement for Notch1 distinguishes 2 phases of definitive hematopoiesis during development.

Authors:  Brandon K Hadland; Stacey S Huppert; Jyotshnabala Kanungo; Yingzi Xue; Rulang Jiang; Thomas Gridley; Ronald A Conlon; Alec M Cheng; Raphael Kopan; Gregory D Longmore
Journal:  Blood       Date:  2004-07-13       Impact factor: 22.113

7.  Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease.

Authors:  Teresa Marafioti; Michela Pozzobon; Martin-Leo Hansmann; Georges Delsol; Stefano A Pileri; David Y Mason
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

8.  Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma.

Authors:  Iwona Wlodarska; Peet Nooyen; Brigitte Maes; José I Martin-Subero; Reiner Siebert; Patrick Pauwels; Chris De Wolf-Peeters; Anne Hagemeijer
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113

9.  Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.

Authors:  H Kanzler; R Küppers; M L Hansmann; K Rajewsky
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

10.  Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.

Authors:  Guocan Wang; Andrea Lunardi; Jiangwen Zhang; Zhenbang Chen; Ugo Ala; Kaitlyn A Webster; Yvonne Tay; Enrique Gonzalez-Billalabeitia; Ainara Egia; David R Shaffer; Brett Carver; Xue-Song Liu; Riccardo Taulli; Winston Patrick Kuo; Caterina Nardella; Sabina Signoretti; Carlos Cordon-Cardo; William L Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2013-06-02       Impact factor: 38.330

View more
  4 in total

1.  MicroRNA-137 represses FBI-1 to inhibit proliferation and in vitro invasion and migration of hepatocellular carcinoma cells.

Authors:  Min Zhu; Mingyang Li; Tao Wang; Enqiang Linghu; Benyan Wu
Journal:  Tumour Biol       Date:  2016-08-04

Review 2.  Regulation of hematopoietic development by ZBTB transcription factors.

Authors:  Takahiro Maeda
Journal:  Int J Hematol       Date:  2016-06-01       Impact factor: 2.490

Review 3.  Role of ZBTB7A zinc finger in tumorigenesis and metastasis.

Authors:  Atul Kumar Singh; Shiv Verma; Prem Prakash Kushwaha; Kumari Sunita Prajapati; Mohd Shuaib; Shashank Kumar; Sanjay Gupta
Journal:  Mol Biol Rep       Date:  2021-05-20       Impact factor: 2.316

4.  LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair.

Authors:  Xue-Song Liu; Gurushankar Chandramouly; Emilie Rass; Yinghua Guan; Guocan Wang; Robin M Hobbs; Anbazhagan Rajendran; Anyong Xie; Jagesh V Shah; Anthony J Davis; Ralph Scully; Andrea Lunardi; Pier Paolo Pandolfi
Journal:  Nat Commun       Date:  2015-10-08       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.